Healthcare Social Network. Share Knowledge, Be Discovered, Find Opportunities. Join Now
XOLAIR | omalizumab
Drug Class: Anti-IgE Antibody
Manufacturer: Genentech USA, Inc
Approval Date: June 2003
What is Xolair and it’s mechanism of action?
Xolair is an injectable biologic medication approved for treatment of chronic allergic asthma and chronic urticaria (hives). Xolair is an anti-IgE medication that binds to and blocks the attachment of immunoglobulin E (IgE) to its receptor on the surface of immune cells called mast cells and basophiles. Antibodies are proteins that protect the body from foreign substances and they are major components of the immune system. IgE is a type of antibody that binds to specific receptors in response to foreign proteins such as bacteria and allergens. IgE activates immune cells causing the release of histamine, a chemical which is responsible for symptoms of asthma and chronic urticaria (hives). Blocking the action of IgE means less histamine is released, reducing symptoms of asthma and hives.
What does Xolair treat?
Who should not use Xolair?
How effective is Xolair?
Allergic Asthma: In a clinical trial studying the efficacy of Xolair, 546 asthmatic patients on a steroid treatment were randomly given Xolair or placebo every 2 to 4 weeks. At the end of 16 weeks with the same dose of steroids 14.6% of patients on Xolair had worsening of asthmatic symptoms compared to 23.3% of patients on placebo. At the end of a second 16-week therapy with a decreased dose of steroids 21.3% of patients on Xolair plus a low dose inhaled steroid had worsening asthma symptoms compared to 32.3% of patients on placebo plus a low dose inhaled steroid.
Chronic Urticaria: In a 12-week long trial, the efficacy of different dosages of Xolair in the treatment of chronic urticaria was studied in comparison to placebo. At the end of 12 weeks 36% of patients treated with Xolair 300 mg, 15% of patients treated with Xolair 150 mg, 12% of the patients treated with Xolair 75 mg, and 9% of patients treated with a placebo had no symptoms of urticaria such as itching or hives.
Interesting facts about Xolair
What is the dosing of Xolair?
Xolair is supplied as a sterile powder in a 5 mL vial containing 150 mg of the drug.
Xolair is administered subcutaneously (under the skin) for both indications. Unlike in treatment of chronic urticaria dosing for allergic asthma is dependent on the blood IgE level. Total IgE level of the blood and body weight is measured to determine the correct patient specific dose. Dosing in treatment of chronic urticaria is not dependent on the blood IgE level or the body weight of the patient.
Only 150 mg can be injected per site. In order to prevent administration of more than 150 mg per site the total dose should be divide and injected at different sites.
What are side effects of Xolair?
Allergic Asthma: Joint pain, Leg/arm pain, fatigue, dizziness, ear ache, fracture, and inflammation of the skin.
Chronic Urticaria: Nausea, headache, common cold, sinus inflammation, upper respiratory infection, joint pain, and cough.
Xolair impairs the immune system and increases the risk of serious infections. Xolair was associated with increased risk of breast, non-melanoma skin, prostate, melanoma, and parotid cancers in clinical trials. Xolair may also cause severe allergic reactions called anaphylaxis.
What is the price of Xolair?
Xolair 150 mg vial costs $969.71
How to obtain prescription cost assistance for Xolair
To download a free drug discount card visit:
Xolair Prescribing Information. Genentech. March 21, 2014
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184
More Articles by Samar Borhani, PharmD Intern